EU Consumer Advocate Opposes Free Pricing for Prescription Drugs

Anna Cavazzini, the chair of the Committee on the Internal Market and Consumer Protection in the European Parliament, has expressed concerns regarding the complete liberalization of prescription drug pricing in the EU. She argues that such a move could disrupt the balance between cost advantages and health protection.

The upcoming ruling by the German Federal Court's I Civil Senate is anticipated to have significant implications for brick-and-mortar pharmacies, as well as for the existing bonus practices of online pharmacies that continually challenge pricing regulations through various discount offers.

Cavazzini emphasized that a more liberal approach to prescription drug distribution, particularly from foreign EU sources, poses risks to consumer safety. She reiterated the importance of existing restrictions on the online sale of prescription medications, stating that while these measures might seem to hinder access to cheaper drugs, they are crucial for ensuring patient safety and safeguarding health data.

She pointed out that EU member states are justified in imposing limitations on the online sale of medicines, as these regulations serve to protect public health, contrasting with the general non-discrimination rules of the European single market.

Cavazzini further cautioned that a total liberalization would complicate the delicate balance between the benefits of lower prices and health security, and would not address existing supply shortages. Instead, she called for a focus on enhancing production capabilities, maintaining local manufacturing, and improving supply chains rather than merely facilitating shipping.

The debate around potential restrictions on prescription drug shipping has resurfaced, with renewed calls for a ban on the online sale of prescription medications. This reflects broader concerns among politicians regarding the impact of e-commerce on local pharmacies.